KCC2b Inhibitors

The chemical class of KCC2b inhibitors revolves around the inhibition of the potassium-chloride cotransporter isoform 2b (KCC2b). KCC2b is crucial for maintaining low intracellular chloride concentration and has a significant role in the inhibitory efficacy of GABAergic transmission. Compounds such as furosemide and bumetanide are loop diuretics that also inhibit cation-chloride cotransporters including KCC2b. They do so by binding to the Cl- binding site, hindering the cotransport process. Another strategy employs the use of more selective inhibitors like VU0463271 and VU0453379 that particularly target KCC2, thereby affecting its isoform KCC2b.

Apart from these, non-specific inhibitors such as niflumic acid and Zn2+ ions operate by interfering with chloride channel activities, thereby indirectly influencing KCC2b functionality. For instance, niflumic acid is a non-selective chloride channel blocker that reduces chloride efflux. WNK-SPAK kinase inhibitors target kinases that phosphorylate KCC2b, affecting its activation state and transport efficiency. These inhibitors showcase that both direct and indirect strategies can be employed to influence KCC2b. This class of inhibitors collectively impinges upon the cotransport function of KCC2b by either directly inhibiting the transporter or by modulating chloride homeostasis, making them an invaluable toolset for dissecting KCC2b's physiological roles.